Arbe Robotics: Why I Still Wouldn't Touch This Stock

Arbe Robotics, a Tel Aviv–based maker of high-resolution 4D imaging radar for ADAS and autonomous vehicles, reported Q3 revenue of $0.3m (backlog $0.2m), a negative gross profit, a $0.08 loss per share and an operating loss of $11.5m; management sees first meaningful auto production revenue in 2027 with design-win announcements and expects most 2026 revenue to come from defense and maritime partnerships and China pilot programs. The company has about $52.6m in cash (management says this funds pursuit of four OEM design wins) but guided FY revenue only $1–2m and adjusted EBITDA losses of $29–35m, implying continued heavy cash burn and dilution risk. Despite promising technical validation and potential premium OEM programs, the stock is priced for a breakout—trailing EV/Sales of ~150x and deeply negative margins—so the author reiterates a Sell given long timelines, execution risk and a valuation that assumes a major, uncertain turnaround.

Analysis

Arbe Robotics reported Q3 revenue of $0.3 million (up from ~$0.1 million year-ago) with a backlog of $0.2 million, a negative gross profit of $0.2 million (improved from negative $0.3 million), a loss per share of $0.08 ($0.01 worse than expectations) and an operating loss of $11.5 million as operating expenses fell to $11.3 million. Adjusted EBITDA loss widened to $9.2 million from $8.2 million despite a modest improvement in net loss to $11.0 million from $12.6 million. Management guides full-year revenue of $1–2 million and adjusted EBITDA losses of $29–35 million, implying sustained heavy cash burn into 2026 and continued dilution risk if milestones slip or additional capital is needed.

The company holds $52.6 million in cash and says that is sufficient to pursue four OEM design wins and planned 2027–2028 production ramps; management expects most 2026 revenue to come from non-automotive defense and maritime contracts and some China pilot revenue via HiRain. Arbe projects first meaningful auto production revenue beginning in 2027, with multiple OEM design decisions expected over the next three quarters, but timelines remain long and dependent on OEM sign-offs and industry macro factors such as tariffs and supply-chain drag.

Market pricing is disconnected from current fundamentals: trailing EV/Sales ~150.5x versus sector 3.44x and trailing Price/Sales ~203x, while trailing gross margin is deeply negative (-140.2%) and return on equity is -142.4%. The valuation rests entirely on a forward-growth narrative (consensus forward revenue growth ~93.2%) and a successful execution of design wins and production ramps; absent near-term proof points the author reiterates a Sell, though the stock may present tactical, short-term trades given oversold technicals and a psychological $1 support level.

Key Decisions for Investors

• Remain on the sidelines or reduce exposure: valuation (EV/Sales and Price/Sales multiples) is priced for a substantial turnaround that the Q3 results do not yet support
• Treat any position as speculative: limit size, expect dilution and continued negative cash flow given guided adjusted EBITDA losses of $29–35 million and a cash balance of $52.6 million
• Monitor three binary catalysts over the next 3–12 months—confirmed OEM design-win announcements, signed production contracts with clear unit volumes/pricing, and visible margin improvement from booked revenue—before increasing exposure
• For tactical traders, consider short-duration, disciplined trades around the reported $1 psychological support and oversold RSI, but avoid converting a short-term bounce into a long-term investment without the proof points above
• If proof points emerge, require at least two consecutive quarters of material revenue growth and a move toward positive gross margin before treating the stock as a buy for core portfolios